M Boscaro
Overview
Explore the profile of M Boscaro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
215
Citations
2570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mondin A, Barbot M, Voltan G, Tizianel I, Vedolin C, Mazzeo P, et al.
J Endocrinol Invest
. 2023 Apr;
46(10):1947-1959.
PMID: 37079177
Purpose: The clinical and hormonal overlap between neoplastic (CS) and non-neoplastic (NNH/pCS) hypercortisolism is a challenge. Various dynamic tests have been proposed to allow an early discrimination between these conditions,...
2.
Ferrante E, Barbot M, Serban A, Ceccato F, Carosi G, Lizzul L, et al.
J Endocrinol Invest
. 2021 Oct;
45(3):629-637.
PMID: 34699044
Purpose: Dynamic testing represents the mainstay in the differential diagnosis of ACTH-dependent Cushing's syndrome. However, in case of undetectable or detectable lesion < 6 mm on MRI, bilateral inferior petrosal...
3.
Ceccato F, Barbot M, Scaroni C, Boscaro M
J Endocrinol Invest
. 2021 Jun;
44(12):2749-2763.
PMID: 34160793
Purpose: Adrenal incidentalomas (AIs) are incidentally discovered adrenal masses, during an imaging study undertaken for other reasons than the suspicion of adrenal disease. Their management is not a minor concern...
4.
Armanini D, Sabbadin C, Boscaro M
J Endocrinol Invest
. 2021 Jan;
44(9):2009-2010.
PMID: 33454931
No abstract available.
5.
Isidori A, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, et al.
J Endocrinol Invest
. 2020 Apr;
43(8):1141-1147.
PMID: 32335855
No abstract available.
6.
Isidori A, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, et al.
J Endocrinol Invest
. 2019 Nov;
43(5):683-696.
PMID: 31773582
Context: Glucocorticoid (GC) replacement therapy in patients with adrenal insufficiency (AI) is life saving. After over 50 years of conventional GC treatment, novel formulations are now entering routine clinical practice....
7.
Albani A, Ferrau F, Ciresi A, Pivonello R, Scaroni C, Iacuaniello D, et al.
Endocrine
. 2018 Feb;
61(1):118-124.
PMID: 29383677
Purpose: Patients with Cushing's disease (CD) experience metabolic alterations leading to increased cardiovascular mortality. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue...
8.
Ceccato F, Antonelli G, Frigo A, Regazzo D, Plebani M, Boscaro M, et al.
J Endocrinol Invest
. 2017 Mar;
40(7):753-760.
PMID: 28247215
Introduction And Aim: Patients with adrenal incidentaloma present a wide range of cortisol secretion, which is not always properly defined by first-line screening tests recommended to rule out Cushing's syndrome...
9.
Ceccato F, Lizzul L, Zilio M, Barbot M, Denaro L, Emanuelli E, et al.
Horm Metab Res
. 2016 Jun;
48(8):514-9.
PMID: 27246620
Central adrenal insufficiency (CAI) in acromegaly may be related to pituitary adenoma or induced by various medical treatments, transsphenoidal neurosurgery (TNS) or radiotherapy (RT), alone or combined. We assessed the...
10.
Trementino L, Michetti G, Angeletti A, Marcelli G, Concettoni C, Cardinaletti C, et al.
Horm Metab Res
. 2016 Apr;
48(5):290-8.
PMID: 27127913
Pasireotide is the first pituitary-directed drug approved for treating patients with Cushing's disease (CD). Our 10-year experience with pasireotide in CD is reported here. Twenty patients with de novo, persistent,...